Sean Rudd

Key publications

Identification and evaluation of small-molecule inhibitors against the dNTPase SAMHD1 via a comprehensive screening funnel
Zhang SM, Paulin CBJ, Michel M, Marttila P, Yagüe-Capilla M, Bwanika HC, Shu H, Papagudi Venkatram R, Wiita E, Jemth AS, Almlöf I, Loseva O, Ortis F, Dirk C, Koolmeister T, Linde E, Lee S, Llona-Minguez S, Haraldsson M, Strömberg K, Homan EJ, Scobie M, Lundbäck T, Helleday T, Rudd SG
bioRxiv 2023

Targeting the DNA damage response and repair in cancer through nucleotide metabolism
Helleday T, Rudd SG
Molecular Oncology 2022

A High-Throughput Enzyme-Coupled Activity Assay to Probe Small Molecule Interaction with the dNTPase SAMHD1
Yagüe-Capilla M, Rudd SG.
2021. Journal of Visualized Experiments; (170), e62503.

Drug synergy scoring using minimal dose response matrices
Mäkelä P, Zhang SM, Rudd SG.
2021. BMC Research Notes; 14;1 27.

Ribonucleotide Reductase Inhibitors Suppress SAMHD1 ara-CTPase Activity Enhancing Cytarabine Efficacy
Rudd SG , Tsesmetzis N, Sanjiv K, Paulin CBJ , Sandhow L, Kutzner J , Myrberg IH, Bunten SS, Axelsson H, Zhang SM, Rasti A, Mäkelä P, Coggins SA, Tao S, Suman S , Branca RM, Mermelekas G, Wiita E, Lee S, Walfridsson J, Schinazi RF, Kim B, Lehtiö J, Rassidakis GZ, Tamm KP, Warpman-Berglund U, Heyman M, Grandér D, Lehmann S, Lundbäck T, Qian H, Henter J-I, Schaller T, Helleday T, Herold N.
2020. EMBO Molecular Medicine; 12(3):e10419

Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism
Tsesmetzis N, Paulin CBJ, Rudd SG, Herold N.
2018. Cancers; 10, 240.

Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies
Herold N, Rudd SG, Ljungblad L, Sanjiv K, Myrberg IH, Paulin CB, Heshmati Y, Hagenkort A, Kutzner J, Page BD, Calderón-Montaño JM, Loseva O, Jemth AS, Bulli L, Axelsson H, Tesi B, Valerie NC, Höglund A, Bladh J, Wiita E, Sundin M, Uhlin M, Rassidakis G, Heyman M, Tamm KP, Warpman-Berglund U, Walfridsson J, Lehmann S, Grandér D, Lundbäck T, Kogner P, Henter JI, Helleday T, Schaller T.
2017. Nature Medicine; 23(2):256-263.

Pathways controlling dNTP pools to maintain genome stability.
Rudd SG, Valerie NC, Helleday T.
2016. DNA Repair; 44:193-204.







Research Interests

Our research centres upon understanding the molecular underpinnings of why some patients respond to cancer therapies – in particular standard-of-care chemotherapeutics – whilst others do not, and using this knowledge as the basis for refining treatment strategies.

The ultimate goal of our research is to provide cancer patients with better treatment options. We believe one way this can be achieved in a timely manner is by focusing research efforts upon commonly used chemotherapeutic agents. These therapies, which form standard-of-care for many cancers, typically kill tumour cells by targeting pan-essential pathways, principally metabolism of the DNA molecule or its nucleotide building blocks (deoxynucleoside triphosphates, dNTPs). In our research program we aim to define the molecular underpinnings of why some cancers respond to these therapies whilst others do not. This information can provide the basis for rational therapy improvements through the identification of biomarkers and therapeutic targets together with the design of mechanism-based drug combinations. We employ a multidisciplinary approach in our research – centred upon biochemical, biophysical, and cell-based methods – and use both hypothesis-driven and hypothesis-free approaches in our efforts to define and exploit the molecular mechanisms underpinning clinical efficacy of chemotherapeutic agents.

In addition, these same pathways which are targeted by commonly used cancer drugs – metabolism of the DNA molecule and its dNTP building blocks – are also fundamental to cancer biology. Key aspects of oncogenesis derive from the interplay of these metabolic pathways, and thus we also investigate this interplay at the molecular level and seek to use knowledge gained in a translationally productive manner.

Group members

Principle Investigator

Sean Rudd


  • Si Min Zhang, Postdoc
  • Miriam Yagüe-Capilla, Postdoc
  • Femke Hormann, Postdoc
  • Christopher Dirks, PhD student


Last updated: 2023-03-02

Content Responsible: Johan Inganni(